Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Feb 1;178(2):176-184.
doi: 10.1001/jamapediatrics.2023.5639.

Maternal Vaccine Effectiveness Against Influenza-Associated Hospitalizations and Emergency Department Visits in Infants

Leila C Sahni  1 , Samantha M Olson  2 , Natasha B Halasa  3 , Laura S Stewart  3 , Marian G Michaels  4 , John V Williams  4 , Janet A Englund  5 , Eileen J Klein  5 , Mary A Staat  6 , Elizabeth P Schlaudecker  6 , Rangaraj Selvarangan  7 , Jennifer E Schuster  7 , Geoffrey A Weinberg  8 , Peter G Szilagyi  9 , Julie A Boom  1 , Manish M Patel  2 , Flor M Muñoz  1 ; New Vaccine Surveillance Network Collaborators
Collaborators, Affiliations
Comment

Maternal Vaccine Effectiveness Against Influenza-Associated Hospitalizations and Emergency Department Visits in Infants

Leila C Sahni et al. JAMA Pediatr. .

Abstract

Importance: Influenza virus infection during pregnancy is associated with severe maternal disease and may be associated with adverse birth outcomes. Inactivated influenza vaccine during pregnancy is safe and effective and can protect young infants, but recent evidence, particularly after the 2009 novel influenza A (H1N1) pandemic, is limited.

Objective: To evaluate the effectiveness of influenza vaccination during pregnancy against laboratory-confirmed influenza-associated hospitalizations and emergency department (ED) visits in infants younger than 6 months.

Design, setting, and participants: This was a prospective, test-negative case-control study using data from the New Vaccine Surveillance Network from the 2016 to 2017 through 2019 to 2020 influenza seasons. Infants younger than 6 months with an ED visit or hospitalization for acute respiratory illness were included from 7 pediatric medical institutions in US cities. Control infants with an influenza-negative molecular test were included for comparison. Data were analyzed from June 2022 to September 2023.

Exposure: Maternal influenza vaccination during pregnancy.

Main outcomes and measures: We estimated maternal vaccine effectiveness against hospitalizations or ED visits in infants younger than 6 months, those younger than 3 months, and by trimester of vaccination. Maternal vaccination status was determined using immunization information systems, medical records, or self-report. Vaccine effectiveness was estimated by comparing the odds of maternal influenza vaccination 14 days or more before delivery in infants with influenza vs those without.

Results: Of 3764 infants (223 with influenza and 3541 control infants), 2007 (53%) were born to mothers who were vaccinated during pregnancy. Overall vaccine effectiveness in infants was 34% (95% CI, 12 to 50), 39% (95% CI, 12 to 58) against influenza-associated hospitalizations, and 19% (95% CI, -24 to 48) against ED visits. Among infants younger than 3 months, effectiveness was 53% (95% CI, 30 to 68). Effectiveness was 52% (95% CI, 30 to 68) among infants with mothers who were vaccinated during the third trimester and 17% (95% CI, -15 to 40) among those with mothers who were vaccinated during the first or second trimesters.

Conclusions and relevance: Maternal vaccination was associated with reduced odds of influenza-associated hospitalizations and ED visits in infants younger than 6 months. Effectiveness was greatest among infants younger than 3 months, for those born to mothers vaccinated during the third trimester, and against influenza-associated hospitalizations.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Sahni reported grants from the US Centers for Disease Control and Prevention (CDC; paid to institution) during the conduct of the study and for participation in the Overcoming COVID-19 network outside the submitted work. Dr Halasa reported grants from the CDC during the conduct of the study and grants from Sanofi, Quidel, and Merck outside the submitted work. Dr Stewart reported grants from the CDC during the conduct of the study. Dr Michaels reported grants from the CDC during the conduct of the study and grants from the National Institutes of Health (NIH) (paid to institution), nonfinancial support from Viracor, and grants from Merck (paid to institution) not related to this work outside the submitted work. Dr Williams reported grants from the CDC during the conduct of the study; personal fees from Quidel (scientific advisory board) and personal fees from GSK (independent data monitoring committee) outside the submitted work. Dr Englund reported grants from the CDC (research support) during the conduct of the study and personal fees from AbbVie, AstraZeneca, Ark Biopharma, Meissa, Moderna, GSK, Pfizer, Shinogi, and SanofiPasteur and grants from AstraZeneca, Pfizer, and GSK outside the submitted work. Dr Staat reported grants from the CDC during the conduct of the study and grants from the NIH, Cepheid, Pfizer, and Merck outside the submitted work. Dr Schlaudecker reported grants from the CDC during the conduct of the study and grants from Pfizer and personal fees from Sanofi Pasteur outside the submitted work. Dr Schuster reported grants from the CDC during the conduct of the study and grants from the CDC (paid to my institution) and the NIH (paid to my institution) and personal fees from the American Association of Medical Colleges outside the submitted work. Dr Weinberg reported grants from the CDC during the conduct of the study and personal fees from Merck (honoraria for writing textbook chapters in Merck Manual) outside the submitted work. Dr Szilagyi reported grants from the CDC during the conduct of the study. Dr Boom reported grants from the CDC New Vaccine Surveillance Network during the conduct of the study. Dr Patel reported personal fees from AbbVie outside the submitted work. Dr Munoz reported grants from Pfizer (paid to institution) and other from Pfizer and Moderna (data and safety monitoring boards) outside the submitted work. No other disclosures were reported.

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Dodds L, McNeil SA, Fell DB, et al. . Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. CMAJ. 2007;176(4):463-468. doi:10.1503/cmaj.061435 - DOI - PMC - PubMed
    1. Mertz D, Kim TH, Johnstone J, et al. . Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ. 2013;347:f5061. doi:10.1136/bmj.f5061 - DOI - PMC - PubMed
    1. US Centers for Disease Control and Prevention . Pregnant people hit hard by flu but many remain unvaccinated. Published December 9, 2022. Accessed April 13, 2023. https://www.cdc.gov/flu/spotlights/2022-2023/pregnant-people-flu-vaccine...
    1. Grohskopf LA, Blanton LH, Ferdinands JM, et al. . Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices—United States, 2022-23 influenza season. MMWR Recomm Rep. 2022;71(1):1-28. doi:10.15585/mmwr.rr7101a1 - DOI - PMC - PubMed
    1. American College of Obstetricians and Gynecologists . Influenza vaccination during pregnancy. Published September 2014. Accessed November 2, 2023. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articl...

Substances